Omeprazole: Difference between revisions

{{Short description|StomachMedication acidto suppressingtreat medicationgastroesophageal reflux disease and other conditions}}

{{Use dmy dates|date=OctoberJanuary 20212024}}

| ATC_supplemental = {{ATC|A02|BC51}}

| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->

| bioavailability= 35–76%<ref>{{cite web | title=Prilosec- omeprazole magnesium capsule, delayed release Prilosec- omeprazole magnesium granule, delayed release | website=DailyMed | date=22 December 2016 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a1b077e6-b070-43f2-a98e-380cc635419d | access-date=15 February 2020 | archive-date=27 December 2019 | archive-url=https://web.archive.org/web/20191227184048/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a1b077e6-b070-43f2-a98e-380cc635419d | url-status=live }}</ref><ref>{{cite journal | vauthors = Vaz-da-Silva M, Loureiro AI, Nunes T, Maia J, Tavares S, Falcão A, Silveira P, Almeida L, Soares-da-Silva P | display-authors = 6 | title = Bioavailability and bioequivalence of two enteric-coated formulations of omeprazole in fasting and fed conditions | journal = Clinical Drug Investigation | volume = 25 | issue = 6 | pages = 391–399 | year = 2005 | pmid = 17532679 | doi = 10.2165/00044011-200525060-00004 | url = http://www.medscape.com/viewarticle/508018 | url-status = live | access-date = 21 October 2018 | s2cid = 22082780 | archive-url = https://web.archive.org/web/20130313204630/http://www.medscape.com/viewarticle/508018 | archive-date = 13 March 2013 }}</ref>

Omeprazole was patented in 1978, and approved for medical use in 1988.<ref>{{cite web | title=Drug Approval Package: Prilosec (Omeprazole) NDA# 019-810s38s50s5 | website=U.S. [[Food and Drug Administration]] (FDA) | date=30 March 2001 | url=https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/019810s38s50s56.cfm | access-date=5 October 2022 | archive-date=1 April 2021 | archive-url=https://web.archive.org/web/20210401151454/https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/019810s38s50s56.cfm | url-status=live }}</ref><ref>{{cite book | vauthors = Fischer J, Ganellin CR |title=Analogue-based Drug Discovery |date=2006 |publisher=John Wiley & Sons |isbn=9783527607495 |page=445 |url=https://books.google.com/books?id=FjKfqkaKkAAC&pg=PA445 |access-date=29 June 2020 |archive-date=3 August 2020 |archive-url=https://web.archive.org/web/20200803230101/https://books.google.com/books?id=FjKfqkaKkAAC&pg=PA445 |url-status=live }}</ref> It is on the [[WHO Model List of Essential Medicines|World Health Organization's List of Essential Medicines]].<ref name="WHO21st">{{cite book | vauthors = ((World Health Organization)) | title = World Health Organization model list of essential medicines: 21st list 2019 | year = 2019 | hdl = 10665/325771 | author-link = World Health Organization | publisher = World Health Organization | location = Geneva | id = WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO | hdl-access=free }}</ref> It is available as a [[generic medication]].<ref name=AHFS2015/> In 20202021, it was the eighth-most commonly prescribed medication in the United States, with more than 5654{{nbsp}}million prescriptions.<ref>{{cite web | title=The Top 300 of 20202021 | url=https://clincalc.com/DrugStats/Top300Drugs.aspx | website=ClinCalc | access-date=14 January 2024 | archive-date=15 January 2024 | archive-url=https://web.archive.org/web/20240115223848/https://clincalc.com/DrugStats/Top300Drugs.aspx | accessurl-datestatus=7 October 2022live }}</ref><ref>{{cite web | title=Omeprazole - Drug Usage Statistics, ClinCalc DrugStats Database | website=ClinCalc | url=https://clincalc.com/DrugStats/Drugs/Omeprazole | access-date=714 OctoberJanuary 20222024 }}</ref> It is also available without a prescription in the United States.<ref>{{cite web |title=Questions and Answers on Prilosec OTC (omeprazole) |url=https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/questions-and-answers-prilosec-otc-omeprazole |website=U.S. [[Food and Drug Administration]] (FDA) |access-date=2 March 2020 |date=3 November 2018 |archive-date=28 August 2021 |archive-url=https://web.archive.org/web/20210828195503/https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/questions-and-answers-prilosec-otc-omeprazole |url-status=live }}</ref><ref>{{cite web | title=Drug Approval Package: Prilosec (Omeprazole Magnesium) NDA #021229 | website=U.S. [[Food and Drug Administration]] (FDA) | url=https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-229_Prilosec.cfm | access-date=6 October 2022 | archive-date=24 January 2022 | archive-url=https://web.archive.org/web/20220124210732/https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-229_Prilosec.cfm | url-status=live }}</ref>

Peptic ulcers may be treated with omeprazole. Infection with ''[[Helicobacter pylori]]'' can be treated by taking omeprazole, [[amoxicillin]], and [[clarithromycin]] together for 7–14 days.<ref>{{cite journal | vauthors = Fuccio L, Minardi ME, Zagari RM, Grilli D, Magrini N, Bazzoli F | title = Meta-analysis: duration of first-line proton-pump inhibitor based triple therapy for Helicobacter pylori eradication | journal = Annals of Internal Medicine | volume = 147 | issue = 8 | pages = 553–562 | date = October 2007 | pmid = 17938394 | doi = 10.7326/0003-4819-147-8-200710160-00008 | s2cid = 11644009 }}</ref> Amoxicillin may be replaced with [[metronidazole]] in patients who are allergic to penicillin.<ref name="Maastricht_2_Consensus_Report">{{cite journal | vauthors = Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El-Omar E, Graham D, Hunt R, Rokkas T, Vakil N, Kuipers EJ | display-authors = 6 | title = Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report | journal = Gut | volume = 56 | issue = 6 | pages = 772–781 | date = June 2007 | pmid = 17170018 | pmc = 1954853 | doi = 10.1136/gut.2006.101634 }}</ref>

There is a possible association between long term use and [[dementia]] which requires further study to confirm.<ref>{{cite journal | vauthors = Eusebi LH, Rabitti S, Artesiani ML, Gelli D, Montagnani M, Zagari RM, Bazzoli F | title = Proton pump inhibitors: Risks of long-term use | journal = Journal of Gastroenterology and Hepatology | volume = 32 | issue = 7 | pages = 1295–1302 | date = July 2017 | pmid = 28092694 | doi = 10.1111/jgh.13737 | doi-access = free }}</ref>

A review article in ''[[U.S. Pharmacist]]'' in 2013 states that long-term use of PPIs is associated with [[Hypocalcaemia|decreased calcium absorption]] (causing increased risk of [[osteoporosis]] and [[Bone fracture|fractures]]), [[Magnesium deficiency|decreased magnesium absorption]] (causing [[Electrolyte imbalance|electrolyte disturbances]]), and increased risk of certain infections such as ''[[C. difficile]]'' and [[community-acquired pneumonia]]. They hypothesize that this is due to decreased stomach acid production.<ref>{{Citecite journal | vauthors = O'Neill LW, Culpepper BL, Galdo JA |title=Long-Term Consequences of Chronic Proton Pump Inhibitor Use | journal = US Pharmacist | date = 2013 | volume = 38 | issue = 12 | pages = 38–42 |url= https://www.uspharmacist.com/article/longterm-consequences-of-chronic-proton-pump-inhibitor-use|access-date=28 December 2020 |archive-date=21 January 2021|archive-url=https://web.archive.org/web/20210121163435/https://www.uspharmacist.com/article/longterm-consequences-of-chronic-proton-pump-inhibitor-use|url-status=live}}</ref>

Almost all [[benzodiazepines]] are metabolised by the CYP3A4 and [[CYP2D6]] pathways, and inhibition of these enzymes results in a higher [[Area under the curve (pharmacokinetics)|area under the curve]] (''i.e.'', the total effect over time of a given dose). Other examples of drugs dependent on CYP3A4 for their metabolism are [[escitalopram]],<ref>{{EMedicine|article|1879354|Selective Serotonin Reuptake Inhibitors and CYP2D6}}</ref> [[warfarin]],<ref name="pmid12724615">{{cite journal | vauthors = Daly AK, King BP | title = Pharmacogenetics of oral anticoagulants | journal = Pharmacogenetics | volume = 13 | issue = 5 | pages = 247–252 | date = May 2003 | pmid = 12724615 | doi = 10.1097/00008571-200305000-00002 }}</ref> [[oxycodone]], [[tramadol]], and [[oxymorphone]]. The concentrations of these drugs may increase if they are used concomitantly with omeprazole.<ref name=Stedman>{{cite journal | vauthors = Stedman CA, Barclay ML | title = Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors | journal = Alimentary Pharmacology & Therapeutics | volume = 14 | issue = 8 | pages = 963–978 | date = August 2000 | pmid = 10930890 | doi = 10.1046/j.1365-2036.2000.00788.x | s2cid = 45337685 }}</ref>

Omeprazole irreversibly blocks the enzyme system on parietal cells that is needed for the secretion of gastric acid. It is a specific H{{sup|+}}/K{{sup|+}}ATPase inhibitor. This is the enzyme needed for the final step in the secretion of gastric acid.<ref name=":0">{{cite journal | vauthors = Howden CW | title = Clinical pharmacology of omeprazole | journal = Clinical Pharmacokinetics | volume = 20 | issue = 1 | pages = 38–49 | date = January 1991 | pmid = 2029801 | doi = 10.2165/00003088-199120010-00003 | s2cid = 25855436 }}</ref>

Omeprazole, as well as other PPIs, are only effective on active H⁺/K⁺-ATPase pumps. These pumps are stimulated in the presence of food to aid in digestion. For this reason, patients should be advised to take omeprazole with a glass of water, on anbefore emptya stomachmeal.<ref>{{cite journal | vauthors = Katz PO, Gerson LB, Vela MF | title = Guidelines for the diagnosis and management of gastroesophageal reflux disease | journal = The American Journal of Gastroenterology | volume = 108 | issue = 3 | pages = 308–28; quiz 329 | date = March 2013 | pmid = 23419381 | doi = 10.1038/ajg.2012.444 | s2cid = 8198975 | doi-access = free }}</ref> Additionally, most sources recommend that after taking omeprazole, at least 30 minutes should be allowed to elapse before eating<ref>{{cite web|url=http://medical-dictionary.thefreedictionary.com/omeprazole|title=Omeprazole, in The Free Medical Dictionary|access-date=11 November 2010|archive-date=12 June 2011|archive-url=https://web.archive.org/web/20110612172513/http://medical-dictionary.thefreedictionary.com/omeprazole|url-status=live}}</ref><ref>{{cite web|url=https://www.drugs.com/monograph/omeprazole.html|title=Omeprazole|publisher=Drugs.com|access-date=11 November 2010|url-status=live|archive-url=https://web.archive.org/web/20110219135631/http://www.drugs.com/monograph/omeprazole.html|archive-date=19 February 2011}}</ref> (at least 60 minutes for immediate-release omeprazole plus sodium bicarbonate products, such as Zegerid),.<ref name="Zegerid OTC FDA label" />

Omeprazole contains a tricoordinated sulfonylsulfinyl sulfur in a pyramidal structure and therefore can exist as either the (''S'')- or (''R'')-[[enantiomer]]s. Omeprazole is a [[racemate]], an equal mixture of the two. In the acidic conditions of the [[canaliculus (parietal cell)|canaliculi]] of [[parietal cells]], both enantiomers are converted to [[achiral]] products ([[sulfenic acid]] and [[sulfenamide]] configurations) which react with a [[cysteine]] group in [[Hydrogen potassium ATPase|H⁺/K⁺ ATPase]], thereby inhibiting the ability of the parietal cells to produce [[gastric acid]].{{citation needed|date=March 2016}}

Omeprazole was first made in 1979 by Swedish AB Hässle, part of [[Astra AB]]. It was the first of the proton pump inhibitors (PPI).<ref>{{Citecite web|url=https://apps.who.int/medicinedocs/en/d/Js4915e/2.5.html|archive-url=https://web.archive.org/web/20101002080328/http://apps.who.int/medicinedocs/en/d/Js4915e/2.5.html|url-status=dead|archive-date=2 October 2010|title=Trends in Drug Patenting - Case Studies: THE CASES: 5. OMEPRAZOLE|website=apps.who.int|access-date=22 August 2019}}</ref><ref name="Fellenius 1981">{{cite journal | vauthors = Fellenius E, Berglindh T, Sachs G, Olbe L, Elander B, Sjöstrand SE, Wallmark B | title = Substituted benzimidazoles inhibit gastric acid secretion by blocking (H+ + K+)ATPase | journal = Nature | volume = 290 | issue = 5802 | pages = 159–161 | date = March 1981 | pmid = 6259537 | doi = 10.1038/290159a0 | s2cid = 4368190 | bibcode = 1981Natur.290..159F }}</ref> [[Astra AB]], now AstraZeneca, launched it as an ulcer medicine under the name Losec in Sweden. It was first sold in the United States in 1989 under the brand name Losec. In 1990, at the request of the [[Food and Drug Administration|U.S. Food and Drug Administration]], the brand name Losec was changed to Prilosec to avoid confusion with the [[diuretic]] Lasix ([[furosemide]]).<ref name=farley>{{cite journal | vauthors = Farley D | title = Making it easier to read prescriptions | journal = FDA Consumer | volume = 29 | issue = 6 | pages = 25–27 | date = July–August 1995 | pmid = 10143448 | url = http://www.thebody.com/content/art13913.html | url-status = dead | access-date = 26 January 2011 | archive-url = https://web.archive.org/web/20120315172345/http://www.thebody.com/content/art13913.html | archive-date = 15 March 2012 }}</ref> The new name led to confusion between omeprazole (Prilosec) and [[fluoxetine]] (Prozac), an [[antidepressant]].<ref name=farley />

Omeprazole was a subject of a patent litigation in the U.S.<ref>{{cite press release | title=AstraZeneca awarded damages in Prilosec patent litigation | website=AstraZeneca | date=3 December 2013 | url=https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-prilosec-patent-litigation-ruling-03122013.html#! {{bare URL inline| access-date=May4 October 2023}}</ref> The invention involved

application of two different coatings to a drug in pill form to ensure, that the Omeprazoleomeprazole did not disintegrate before reaching its intended site of action in stomach. Although the solution by means of two coating was obvious, the patent was found valid, because the source of the problem was non-obvious and was discovered by the patentee.<ref>{{cite web | url=https://scholar.google.com/scholar_case?case=12553883911671736992&q=+In+re+Omeprazole+Patent+Litigation&hl=en&as_sdt=40000003 | title=IN RE OMEPRAZOLE PATENT LITIGATION, Court of Appeals, Federal Circuit 2011 - Google Scholar }}</ref>

In September 2023, AstraZeneca announced it would pay $425 million to settle product liability litigations against Prilosec in the United States.<ref>{{cite news |date=3 October 2023 |title=AstraZeneca to pay $425 mln to settle Nexium, Prilosec litigation in US |work=Reuters |url=https://www.reuters.com/legal/astrazeneca-pay-425-mln-settle-nexium-prilosec-litigation-us-2023-10-03/ |access-date=3 October 2023}}</ref>

==Society= andBrand culturenames ===

[[Category:AstraZenecaDrugs brandsdeveloped by AstraZeneca]]

[[Category:BayerDrugs brandsdeveloped by Bayer]]